Tema Etfs LLC Takes $4.42 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Tema Etfs LLC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,981 shares of the pharmaceutical company's stock, valued at approximately $4,422,000. Vertex Pharmaceuticals makes up about 1.8% of Tema Etfs LLC's portfolio, making the stock its 18th biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brown Lisle Cummings Inc. purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at $30,000. Sugar Maple Asset Management LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at $35,000. Golden State Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at $37,000. Truvestments Capital LLC lifted its holdings in Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after purchasing an additional 23 shares in the last quarter. Finally, Midwest Capital Advisors LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VRTX shares. HC Wainwright restated a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Finally, Leerink Partners reissued a "market perform" rating and issued a $503.00 price objective (down previously from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Thirteen research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $515.04.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares in the company, valued at $27,825,928.26. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,813 shares of company stock worth $1,889,514 over the last three months. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Stock Up 1.5%

Shares of VRTX stock traded up $6.52 during trading hours on Tuesday, reaching $447.18. 1,510,440 shares of the stock were exchanged, compared to its average volume of 1,412,201. The business's fifty day moving average is $480.76 and its two-hundred day moving average is $464.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a market capitalization of $114.83 billion, a P/E ratio of -203.26, a P/E/G ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.76 earnings per share. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.